Last reviewed · How we verify
NCT05189158
Ventilatory Responses to Hypercapnic and Hypoxic Conditions in Hyperventilants
NA trial testing Hypercapnic hyperoxic ventilatory response in Hyperventilation Syndrome in 24 participants. Completed in 15 October 2021.
15 October 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Saint Pierre |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 24 |
| Start date | 15 October 2021 |
| Primary completion | 15 October 2021 |
| Estimated completion | 15 October 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Hypercapnic hyperoxic ventilatory response
- Hypoxic eucapnic ventilatory response
Conditions studied
- Hyperventilation Syndrome — all drugs for Hyperventilation Syndrome →
- Hypercapnia — all drugs for Hypercapnia →
- Hypoxia — all drugs for Hypoxia →
Sponsor
Centre Hospitalier Universitaire Saint Pierre
Who can join
Adults 18 to 99, any sex, with Hyperventilation Syndrome or Hypercapnia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
For almost a century, many hypotheses have converged on the idea of altered chemosensitivity in patients suffering from hyperventilation syndrome (HVS). Given the evolution of current technical equipment and the ability to maximise true positives in HVS ( using the revised hyperventilation provocation test), it seems reasonable to investigate central and peripheral chemosensitivities in HVS subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05189158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire Saint Pierre trials
Trials by the same sponsor.
- NCT06814600 — Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients · recruiting
- NCT06214312 — Pulmonary Ultrasound for the Assessment of Atelectasis in Anesthetized Children Using a Laryngeal Mask Airway. · completed
- NCT05856396 — Maternal Determinants of Infant Immunity to Pertussis · Phase 4 · completed
- NCT05898737 — Nociception Level Index (NOL Index) for Obstetrical Pain Assessment Under Epidural Analgesia. · unknown
- NCT05848531 — Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05189158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Saint Pierre
- Last refreshed: 12 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing